Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI:  10.1158/1078-0432.CCR-15-1125)

Sherene Loi; Sathana Dushyanthen; Paul A. Beavis; Roberto Salgado; Carsten Denkert; Peter Savas; Susan Combs; David L. Rimm; Jennifer M. Giltnane; Monica V. Estrada; Violeta Sanchez; Melinda E. Sanders; Rebecca S. Cook; Mark A. Pilkinton; Simon A. Mallal; Kai Wang; Vincent A. Miller; Phil J. Stephens; Roman Yelensky; Franco D. Doimi; Henry Gomez; Sergey V. Ryzhov; Phillip K. Darcy; Carlos L. Arteaga; Justin M. Balko

doi:10.1158/1078-0432.CCR-18-4264

Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

Sherene Loi
, Sathana Dushyanthen
, Paul A. Beavis
, Roberto Salgado
, Carsten Denkert
, Peter Savas
, Susan Combs
, David L. Rimm
, Jennifer M. Giltnane
, Monica V. Estrada
, Violeta Sanchez
, Melinda E. Sanders
, Rebecca S. Cook
, Mark A. Pilkinton
, Simon A. Mallal
, Kai Wang
, Vincent A. Miller
, Phil J. Stephens
, Roman Yelensky
, Franco D. Doimi

Henry Gomez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko

Facultad de Medicina

Producción científica: Contribución a una revista › Comentario/Debate

16 Citas (Scopus)

Resumen

In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Idioma original	Inglés
Páginas (desde-hasta)	1437
Número de páginas	1
Publicación	Clinical Cancer Research
Volumen	25
N.º	4
DOI	https://doi.org/10.1158/1078-0432.CCR-18-4264
Estado	Publicada - 15 feb. 2019

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1158/1078-0432.CCR-18-4264

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., Sanchez, V., Sanders, M. E., Cook, R. S., Pilkinton, M. A., Mallal, S. A., Wang, K., Miller, V. A., Stephens, P. J., Yelensky, R., ... Balko, J. M. (2019). Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125). Clinical Cancer Research, 25(4), 1437. https://doi.org/10.1158/1078-0432.CCR-18-4264

Loi, Sherene ; Dushyanthen, Sathana ; Beavis, Paul A. et al. / Correction : RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125). En: Clinical Cancer Research. 2019 ; Vol. 25, N.º 4. pp. 1437.

@article{0a9c79d25ddb4f00ab0af0af2a756c9d,

title = "Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)",

abstract = "In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.",

author = "Sherene Loi and Sathana Dushyanthen and Beavis, \{Paul A.\} and Roberto Salgado and Carsten Denkert and Peter Savas and Susan Combs and Rimm, \{David L.\} and Giltnane, \{Jennifer M.\} and Estrada, \{Monica V.\} and Violeta Sanchez and Sanders, \{Melinda E.\} and Cook, \{Rebecca S.\} and Pilkinton, \{Mark A.\} and Mallal, \{Simon A.\} and Kai Wang and Miller, \{Vincent A.\} and Stephens, \{Phil J.\} and Roman Yelensky and Doimi, \{Franco D.\} and Henry Gomez and Ryzhov, \{Sergey V.\} and Darcy, \{Phillip K.\} and Arteaga, \{Carlos L.\} and Balko, \{Justin M.\}",

note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

month = feb,

day = "15",

doi = "10.1158/1078-0432.CCR-18-4264",

language = "Ingl{\'e}s",

volume = "25",

pages = "1437",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "4",

}

Loi, S, Dushyanthen, S, Beavis, PA, Salgado, R, Denkert, C, Savas, P, Combs, S, Rimm, DL, Giltnane, JM, Estrada, MV, Sanchez, V, Sanders, ME, Cook, RS, Pilkinton, MA, Mallal, SA, Wang, K, Miller, VA, Stephens, PJ, Yelensky, R, Doimi, FD, Gomez, H, Ryzhov, SV, Darcy, PK, Arteaga, CL & Balko, JM 2019, 'Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)', Clinical Cancer Research, vol. 25, n.º 4, pp. 1437. https://doi.org/10.1158/1078-0432.CCR-18-4264

Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125). / Loi, Sherene; Dushyanthen, Sathana; Beavis, Paul A. et al.
En: Clinical Cancer Research, Vol. 25, N.º 4, 15.02.2019, p. 1437.

Producción científica: Contribución a una revista › Comentario/Debate

TY - JOUR

T1 - Correction

T2 - RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

AU - Loi, Sherene

AU - Dushyanthen, Sathana

AU - Beavis, Paul A.

AU - Salgado, Roberto

AU - Denkert, Carsten

AU - Savas, Peter

AU - Combs, Susan

AU - Rimm, David L.

AU - Giltnane, Jennifer M.

AU - Estrada, Monica V.

AU - Sanchez, Violeta

AU - Sanders, Melinda E.

AU - Cook, Rebecca S.

AU - Pilkinton, Mark A.

AU - Mallal, Simon A.

AU - Wang, Kai

AU - Miller, Vincent A.

AU - Stephens, Phil J.

AU - Yelensky, Roman

AU - Doimi, Franco D.

AU - Gomez, Henry

AU - Ryzhov, Sergey V.

AU - Darcy, Phillip K.

AU - Arteaga, Carlos L.

AU - Balko, Justin M.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

AB - In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

UR - https://www.scopus.com/pages/publications/85061565447

U2 - 10.1158/1078-0432.CCR-18-4264

DO - 10.1158/1078-0432.CCR-18-4264

M3 - Comentario/Debate

C2 - 30770496

AN - SCOPUS:85061565447

SN - 1078-0432

VL - 25

SP - 1437

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 4

ER -

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P et al. Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125). Clinical Cancer Research. 2019 feb. 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264